Medisca Removes Potential Allergens From Topical Products and Provides Essential BUD Testing to Support Clients

MONTREAL--(BUSINESS WIRE)--In response to requirements from Health Canada and other international health organizations, Medisca, a global leader in the personalized pharmaceutical industry, has removed potential allergens methylisothiazolinone and methylchloroisothiazolinone (MI/MCI), from flagship products. MI/MCI are chemicals commonly used as preservatives in “leave-in” cosmetics and other topical products, but when used in higher concentrations, MI/MCI may cause rashes and other symptoms.

Medisca reformulated their products known as “VersaPro Gel” and “VersaPro Cream” to remove MI/MCI chemicals, and will phase out previous formulations by July 2021. These improved products will maintain similar appearance, texture and functionality, and will come at no extra cost.

When using any newly reformulated product for extended Beyond Use Dates (BUDs), compounding pharmacists must conduct stability testing, a process that identifies the potential shelf life of a medication, including potency, degradation levels, and other measures for patient safety. Medisca has proactively conducted these tests in order to save their clients the time and money necessary to improve access and ensure safety.

“We are committed to staying ahead of international standards when providing products for our clients,” said Andrew Rowe, Senior Vice President at Medisca. “We are also heavily invested in providing our pharmacists with a databank of studies and formulas to convert these products into the best quality care for their patients.”

Medisca maintains this BUD databank free of charge to Medisca customers, which includes 20 new topical studies, 70 oral studies, and others set for publication in the coming months. The company also provides online resources to help educate and assist pharmacists in understanding BUD studies and how to use them.

Medisca is the leader in providing turnkey solutions to the pharmaceutical compounding industry and allied health care professionals worldwide. Through its global partners, LP3 Network and Medisca Network, Medisca is committed to being a complete resource for prescribers, pharmacists and pharmacy technicians engaged in personalized medicine by offering educational trainings, products, and support. Founded in 1989, the company has locations in Canada, the United States and Australia, optimizing its service to the international market. For more information about Medisca, please visit www.medisca.com and follow us on Twitter at @medisca.

Ekaterina Dobrokhotova
6090 Boulevard Henri-Bourassa Quest
St. Laurent, Quebec, H4R 3A6
Medisca.com
1-800-932-1039